Bayer AG is set to face a second U.S. jury over allegations that its popular glyphosate-based weed killer Roundup causes cancer, six months after the company’s share price was rocked by a $289 million verdict in California state court.
A lawsuit by California resident Edwin Hardeman against the company was scheduled to begin on [February 25] in federal rather than state court. The trial is also a test case for a larger litigation. More than 760 of the 9,300 Roundup cases nationwide are consolidated in the federal court in San Francisco that is hearing Hardeman’s case.
Hardeman began using the Roundup brand herbicide with glyphosate in the 1980s to control poison oak and weeds on his property and sprayed “large volumes” of the chemical for many years on a regular basis, according to court documents. He was diagnosed with non-Hodgkin’s lymphoma, a cancer of the lymph system, in February 2015 and filed his lawsuit a year later.
But Hardeman has a history of hepatitis C, a risk factor for developing lymphoma. Bayer in court filings also said the majority of non-Hodgkin’s lymphoma incidents are idiopathic, or have no known cause.
Read full, original article: Bayer faces second trial over alleged Roundup cancer risk